Gemcitabine, etoposide, cisplatin, and dexamethasone in patients with refractory or relapsed non-Hodgkin's lymphoma

Korean Journal of Internal Medicine

Volumn 24, Issue 1, 2009, Pages 37-42

  Kim, Ki Hyang ^a   Joo, Young Don ^a   Sohn, Chang Hak ^a   Shin, Ho Jin ^b   Chung, Joo Seop ^b   Cho, Goon Jae ^b   Shin, Sung Hoon ^c   Kim, Yang Soo ^c   Lee, Won Sik ^a  

^a Inje University College of Medicine   (South Korea)

^b Pusan National University Hospital   (South Korea)

^c Kosin University   (South Korea)

Author keywords

Gemcitabine; Non Hodgkin's lymphoma; Refractory or relapsed

Indexed keywords

CD34 ANTIGEN; CISPLATIN; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; GEMCITABINE; MEPREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT;

ADOLESCENT; ADULT; AGED; ALOPECIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RELAPSE; CLINICAL ARTICLE; CONTINUOUS INFUSION; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; LARGE CELL LYMPHOMA; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; SALVAGE THERAPY; STOMATITIS; T CELL LYMPHOMA; THROMBOCYTOPENIA; TREATMENT RESPONSE; BIOPSY; CLINICAL TRIAL; COMPARATIVE STUDY; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; CISPLATIN; DEOXYCYTIDINE; DEXAMETHASONE; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 64249111652     PISSN: 12263303     EISSN: 20056648     Source Type: Journal    
DOI: 10.3904/kjim.2009.24.1.37     Document Type: Article

References (22)

1. Hickish T, Roldan A, Cunningham D, et al. EPIC: an effective low toxicity regimen for relapsing lymphoma. Br J Cancer 1993;68:599-604. (Pubitemid 23258469)
2. Sweetenham JW, Johnson PW. ESHAP chemotherapy for relapsed/refractory non-Hodgkin's lymphoma. J Clin Oncol 1994;12:2766a.
3. Bernell P, Ohm L. Promising activity of gemcitabine in refractory high-grade non-Hodgkin's lymphoma. Br J Haematol 1998;101:203-204. (Pubitemid 28197795)
4. Fossa A, Santoro A, Hiddemann W, et al. Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 1999;17:3786-3792.
5. Sallah S, Wan JY, Nguyen NP. Treatment of refractory T-cell malignancies using gemcitabine. Br J Haematol 2001;113:185-187. (Pubitemid 32423320)
6. Santoro A, Bredenfeld H, Devizzi L, et al. Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study. J Clin Oncol 2000;18:2615-2619. (Pubitemid 30432529)
7. Savage DG, Rule SA, Tighe M, et al. Gemcitabine for relapsed or resistant lymphoma. Ann Oncol 2000;11:595-597.
8. Zinzani PL, Bendandi M, Stefoni V, et al. Value of gemcitabine treatment in heavily pretreated Hodgkin's disease patients. Haematologica 2000;85:926-929. (Pubitemid 30769838)
9. Chau I, Harries M, Cunningham D, et al. Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply repalsed Hodgkin's and non-Hodgkin's lymphoma. Br J Haematol 2003;120:970-977. (Pubitemid 36411555)
10. Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization classification of tumors, pathology and genetics of tumors of hematopoietic and lymphoid tissues. Lyon, IARC Press, 2001.
11. Cheson BD, Horning SJ, Coiffler B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999;17:1244.
12. Storniolo AM, Allerhiligen SR, Pearce HL. Preclinical, pharmacologic and phase I studies of gemcitabine. Semin Oncol 1997;24:2-7.
13. Grunewald R, Kanraejan H, Keating MJ, Abbruzzese J, Tarassoff P, Plungett W. Pharmacologically directed design of the dose rate and schedule of 2′,2′-difluorodeoxycitidine (gemcitabine) administration in- leukemia. Cancer Res 1990;50:6823-6826. (Pubitemid 20361074)
14. Velaquez WS, Cabanillas F, Salvador P, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988;71:117-122. (Pubitemid 18050400)
15. Crump M, Baetz T, Couban S, et al. Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). Cancer 2004;101:1835-1842.
16. Choi CW, Paek CW, Seo JH, et al. ESHAP salvage therapy for relapsed or refractory non-Hodgkin's lymphoma. J Korean Med Sci 2002;17:621-624.
17. Dumontet C, Morschhauser F, Solal-Celigny P, et al. Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma. Br J Haematol 2001;13:772-778. (Pubitemid 32524402)
18. Kroep JR, Peters GJ, van Moorsel CJ, et al. Gemcitabinecisplatin: a schedule finding study. Ann Oncol 1999;10:1503-1510.
19. van Moorsel CJ, Kroep JR, Pinedo HM, et al. Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors. Ann Oncol 1999;10:441-448. (Pubitemid 29236422)
20. Nagourney RA, Link JS, Blitzer JB, Forsthoff C, Evans SS. Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer patients. J Clin Oncol 2000;18:2245-2249. (Pubitemid 30350216)
21. Peters GJ, Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Braakhuis B. Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 1995;22(4 Suppl 11):72-79.
22. Zinzani PL, Baliva G, Magagnoli M, et al. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. J Clin Oncol 2000;18:2603-2606. (Pubitemid 30432527)